1 Rheumatology Division, Escola Paulista de Medicina (UNIFESP-EPM), Universidade Federal de São Paulo, São Paulo, Brazil.
2 Department of Diagnostic Imaging, Escola Paulista de Medicina (UNIFESP-EPM), Universidade Federal de São Paulo, São Paulo, Brazil.
Clin Rehabil. 2019 Jun;33(6):1015-1026. doi: 10.1177/0269215519827996. Epub 2019 Feb 19.
To compare the effectiveness of intra-articular injection (IAI) with Botulinum toxin type A (BTA), triamcinolone hexacetonide (TH), and saline in primary knee osteoarthritis.
A randomized controlled trial, with blinded patients and assessor.
Outpatient rheumatology service.
Patients with knee osteoarthritis grades II and III.
Patients received IAI with 100 IU BTA, 40 mg TH, or isotonic saline solution (SS) 0.9%.
Patients were assessed at baseline and at 4, 8, and 12 weeks with the following instruments: visual analog scale for pain during movement (VASm; primary outcome) and visual analog scale for pain at rest (VASr), Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) questionnaire, 6-minute walk test, Timed Up and Go test, Short Form (SF)-36 questionnaire, range of motion of knee, and ultrasound (US) measurement of synovial hypertrophy.
In total, 105 patients were randomized, with 35 in each group; 96 were female (91.4%) and 9 were male (8.6%), with a mean age of 64.2 years (±6.9). At 12 weeks, the TH group showed better results only for VASm. At four weeks, the TH group showed better results than the BTA and SS groups for VASm (-68.9% (37.8) vs. -35.3% (40.3) vs. -35.9% (51.4)), WOMAC pain (-56.0% (30.7) vs. -30.8% (34.3) vs. -30.0% (39.9)), WOMAC stiffness (-53.4% (38.4) vs. -17.2% (59.3) vs. -17.3% (78.1)), WOMAC function (-48.2% (34.6) vs. 30.8% (33.6) vs. -13.6% (64.9)), WOMAC total score (-51.2% (31.0) vs. -30.9% (30.0) vs. -18.8% (54.8)), and US measurement of synovial hypertrophy (-11.6% (44.9) vs. -1.5% (47.9) vs. +28.6% (81.3)).
IAI with TH had a higher effectiveness than that with TBA or SS in the short-term assessment (four weeks) for pain in movement, WOMAC, and US measurement of synovial hypertrophy.
比较关节内注射(IAI)肉毒毒素 A(BTA)、曲安奈德己酮、生理盐水治疗膝关节骨关节炎的效果。
随机对照试验,患者和评估者设盲。
门诊风湿病科。
膝关节骨关节炎Ⅱ级和Ⅲ级患者。
患者接受 100IU BTA、40mg 曲安奈德己酮或等渗盐水(SS)0.9%IAI。
患者在基线、4、8、12 周时采用以下工具评估:运动时疼痛的视觉模拟量表(VASm;主要结局)、静息时疼痛的视觉模拟量表(VASr)、西部安大略省和麦克马斯特大学骨关节炎指数(WOMAC)问卷、6 分钟步行试验、计时起立行走测试、SF-36 问卷、膝关节活动度和超声(US)测量滑膜增生。
共纳入 105 例患者,每组 35 例;96 例女性(91.4%),9 例男性(8.6%),平均年龄 64.2±6.9 岁。12 周时,曲安奈德己酮组仅在 VASm 方面的结果更好。4 周时,曲安奈德己酮组在 VASm(-68.9%(37.8)比-35.3%(40.3)比-35.9%(51.4))、WOMAC 疼痛(-56.0%(30.7)比-30.8%(34.3)比-30.0%(39.9))、WOMAC 僵硬(-53.4%(38.4)比-17.2%(59.3)比-17.3%(78.1))、WOMAC 功能(-48.2%(34.6)比 30.8%(33.6)比-13.6%(64.9))、WOMAC 总分(-51.2%(31.0)比-30.9%(30.0)比-18.8%(54.8))和 US 测量滑膜增生(-11.6%(44.9)比-1.5%(47.9)比+28.6%(81.3))方面的效果优于 BTA 或 SS。
短期(4 周)评估时,曲安奈德己酮 IAI 治疗运动时疼痛、WOMAC 和 US 测量滑膜增生的效果优于 BTA 或 SS。